Literature DB >> 22389266

Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.

Yanli Li1, Yi Gong, Linglin Li, Hamid M Abdolmaleky, Jin-Rong Zhou.   

Abstract

Lung cancer is the leading cause of cancer death in the world, and the searching for novel efficacious and safe agents for lung cancer prevention remains the top priority of lung cancer research. In the present study, we evaluated the effect of bioactive tanshinones from a Chinese herb Salvia miltiorrhiza, cryptotanshinone (CT), tanshinone I (T1) and tanshinone IIA (T2A), on the proliferation inhibition of lung cancer cell lines. Tanshinones inhibited the lung cancer cell proliferation in vitro, with T1 the most potent, via cell cycle arrest and apoptosis induction. Gene function assay showed that Aurora A knockdown by siRNA dramatically eliminated the T1 activity in vitro, suggesting that Aurora A is an important functional target for T1. We further evaluated the effectiveness of T1 on the growth of H1299 nonsmall lung cancer cell in a mouse model. Tanshinone I inhibited the growth of H1299 lung tumor in a dose-dependent manner. Tanshinone I at 200 mg/kg body weight significantly reduced final tumor weight by 34% (P < 0.05) associated with inhibiting proliferation and inducing apoptosis of lung cancer cells by 54% (P < 0.001) and 193% (P < 0.001), respectively, inhibiting lung tumor angiogenesis by 72% (P < 0.001), and reducing Aurora A expression by 67% (P < 0.001). On the other hand, T1 did not significantly alter food intake or body weight. Our results provided experimental evidence to suggest that T1 may be an efficacious and safe agent for the prevention of lung cancer progression and Aurora A may be an important molecular target for T1 action against lung cancer.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22389266      PMCID: PMC3376178          DOI: 10.1002/mc.21888

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

1.  A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authors:  Güllü Görgün; Elisabetta Calabrese; Teru Hideshima; Jeffrey Ecsedy; Giulia Perrone; Mala Mani; Hiroshi Ikeda; Giada Bianchi; Yiguo Hu; Diana Cirstea; Loredana Santo; Yu-Tzu Tai; Sabikun Nahar; Mei Zheng; Madhavi Bandi; Ruben D Carrasco; Noopur Raje; Nikhil Munshi; Paul Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-09       Impact factor: 22.113

2.  [Influence of blood-activating drugs on adhesion and invasion of cells in lung cancer patients].

Authors:  P Zhang; Y Pei; Y Qi
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1999-02

3.  Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey.

Authors:  D M Eisenberg; R B Davis; S L Ettner; S Appel; S Wilkey; M Van Rompay; R C Kessler
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

4.  Stable knockdown of Aurora-A by vector-based RNA interference in human esophageal squamous cell carcinoma cell line inhibits tumor cell proliferation, invasion and enhances apoptosis.

Authors:  Xiaoxia Wang; Lijia Dong; Jun Xie; Tong Tong; Qimin Zhan
Journal:  Cancer Biol Ther       Date:  2009-10       Impact factor: 4.742

5.  Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis.

Authors:  Jia-Jun Liu; Yong Zhang; Dong-Jun Lin; Ruo-Zhi Xiao
Journal:  Oncol Rep       Date:  2009-04       Impact factor: 3.906

6.  Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios.

Authors:  Chin-Cheng Su; Yi-Hsiang Lin
Journal:  Int J Mol Med       Date:  2008-09       Impact factor: 4.101

7.  Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation.

Authors:  W Y W Lee; L C M Chiu; J H K Yeung
Journal:  Food Chem Toxicol       Date:  2007-08-21       Impact factor: 6.023

Review 8.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

9.  Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model.

Authors:  Masafumi Kumano; Hideaki Miyake; Tomoaki Terakawa; Junya Furukawa; Masato Fujisawa
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

10.  Aurora-A kinase is required for centrosome maturation in Caenorhabditis elegans.

Authors:  E Hannak; M Kirkham; A A Hyman; K Oegema
Journal:  J Cell Biol       Date:  2001-12-17       Impact factor: 10.539

View more
  18 in total

1.  Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules.

Authors:  Raman Kumar; Nidhi Gupta; Alpana Sharma
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

2.  Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function.

Authors:  Yi Gong; Yanli Li; Hamid M Abdolmaleky; Linglin Li; Jin-Rong Zhou
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

3.  Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks.

Authors:  L Xu; J-M Feng; J-X Li; J-M Zhu; S-S Song; L-J Tong; Y Chen; X-Y Yang; Y-Y Shen; F-L Lian; Y-P Li; D-H Lin; J Ding; Z-H Miao
Journal:  Cell Death Dis       Date:  2013-11-07       Impact factor: 8.469

4.  Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.

Authors:  Li Wang; Jianzhong Wu; Jianwei Lu; Rong Ma; Dawei Sun; Jinhai Tang
Journal:  Mol Med Rep       Date:  2014-10-30       Impact factor: 2.952

5.  Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer.

Authors:  Zhong-Liang Ma; Bing-Jie Zhang; D Tao Wang; Xue Li; Jia-Li Wei; Bo-Tao Zhao; Yan Jin; Yan-Li Li; You-Xin Jin
Journal:  Oncotarget       Date:  2015-08-21

6.  A promising "TRAIL" of tanshinones for cancer therapy.

Authors:  Tsing-Fen Ho; Chia-Che Chang
Journal:  Biomedicine (Taipei)       Date:  2015-11-28

7.  Modulation of G2/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts.

Authors:  Zhicheng Chen; Bo Zhang; Feng Gao; Renjie Shi
Journal:  Oncol Lett       Date:  2017-11-23       Impact factor: 2.967

8.  Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.

Authors:  Ching-Yuan Wu; Yao-Hsu Yang; Yin-Yin Lin; Feng-Che Kuan; Yu-Shin Lin; Wei-Yu Lin; Ming-Yen Tsai; Jia-Jing Yang; Yu-Ching Cheng; Li-Hsin Shu; Ming-Chu Lu; Yun-Ju Chen; Kuan-Der Lee; Hong-Yo Kang
Journal:  Oncotarget       Date:  2017-06-20

9.  Activation of JNK and IRE1 is critically involved in tanshinone I-induced p62 dependent autophagy in malignant pleural mesothelioma cells: implication of p62 UBA domain.

Authors:  Jihyun Lee; Eun Jung Sohn; Sangwook Yoon; Gunho Won; Chang Geun Kim; Ji Hoon Jung; Sung-Hoon Kim
Journal:  Oncotarget       Date:  2017-04-11

Review 10.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.